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Aims: To test if 6 months' intervention with dietary nitrate and spironolactone could
affect carotid subclinical atherosclerosis and stiffness, respectively, vs. placebo/
doxazosin, to control for blood pressure (BP).
Methods: A subgroup of participants in our double-blind, randomized-controlled,
factorial VaSera trial had carotid imaging. Patients with hypertension and with/at risk
of type 2 diabetes were randomized to active nitrate-containing beetroot juice or
placebo nitrate-depleted juice, and spironolactone or doxazosin. Vascular ultrasound
for carotid diameter (CD, mm) and intima–media thickness (CIMT, mm) was
performed at baseline, 3- and 6-months. Carotid local stiffness (CS, m/s) was
estimated from aortic pulse pressure (Arteriograph) and carotid lumen area. Data
were analysed by modified intention to treat and using mixed-model effect, adjusted
for confounders.
Results: In total, 93 subjects had a baseline evaluation and 86% had follow-up data.
No statistical interactions occurred between the juice and drug arms and BP was
similar between the juices and between the drugs. Nitrate-containing vs. placebo
juice significantly lowered CIMT (0.06 [95% confidence interval 0.12, 0.01], P
= .034), an overall difference of 8% relative to baseline; but had no effect on CD or
CS. Doxazosin appeared to reduce CS from baseline (0.34 [0.62, 0.06]) however,
no difference was detected vs. spironolactone (0.15 [0.46, 0.16]). No differences
were detected between spironolactone or doxazosin on CIMT and CD.
Conclusions: Our results show that 6 months' intervention with dietary nitrate influ-
ences vascular remodelling, but not carotid stiffness or diameter. Neither spironolactone
nor doxazosin had a BP-independent effect on carotid structure and function.
Principal investigator: The authors confirm that the Principal Investigator for this paper is Professor J. Kennedy Cruickshank and that he had direct clinical responsibility for patients.Clinical trial
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1 | INTRODUCTION
Patients with type 2 diabetes (T2DM) are at increased risk of coronary
heart disease, ischaemic stroke and vascular deaths. According to current
guidelines, evaluation of cardiovascular risk in asymptomatic patients
with T2DM should include the assessment of atherosclerotic burden.
Although less powerful than coronary artery calcium screening for risk
stratification, carotid intima–media thickness (CIMT) has been used as a
widely available, simple and noninvasive marker of subclinical atheroscle-
rosis. Also, some earlier studies suggested that CIMT may be a better
tool than coronary artery calcium for predicting stroke,1,2 and it has been
associated with coronary heart disease.3,4 As a measure of arterial wall
thickness, an increased CIMT is considered to represent a quantitative
expression of atherosclerotic burden and endothelial dysfunction.5–9
Key steps in the atherogenic process include a decline in nitric
oxide (NO) synthesis, increased reactive oxygen species production,
diminished NO bioavailability and endothelial dysfunction.10 Dietary
nitrate, as found in green leafy vegetables and beetroot, is a source of
NO via the nitrate (NO3
)-nitrite (NO2
)-NO pathway and confers
several beneficial actions on the cardiovascular system.11,12 Studies in
humans show that provision of dietary nitrate may enhance
endothelial function,13 and suppresses microvascular inflammation.14
With respect to atherogenesis, studies in animals show that
nitrate/nitrite may limit the development of intimal hyperplasia and
smooth muscle cell proliferation, vascular ageing and atherosclero-
sis.15 Alef et al., found that sodium nitrite (24-h oral supplementation,
a single intraperitoneal injection or via inhalation), limited intimal
hyperplasia and smooth muscle cell proliferation following balloon
injury of the rat carotid artery, whereas a low nitrate/nitrite diet
increased intimal hyperplasia; notably, this could be reversed by the
late introduction of nitrite.16 Studies performed in mice found mixed
effects. Fourteen weeks' supplementation with sodium nitrate had no
effect on atherogenesis in low density lipoprotein receptor knockout
mice (LDLr/).17 However, studies in apolipoprotein E knockout
(ApoE/) mice have shown benefit. Ten weeks' supplementation
with low and moderate dose nitrate significantly improved endothelial
function and atherosclerotic plaque composition in ApoE/ mice fed
a high-fat diet.18 Twelve weeks' supplementation with dietary nitrate,
caused reductions in macrophage accumulation and elevations in
smooth muscle accumulation within atherosclerotic plaques of
ApoE/ mice, suggesting plaque stabilization, albeit without effect
on total plaque area; effects were seen with normal chow and high fat
diets.19 Eight weeks' nitrate supplementation decreased atheroscle-
rotic plaque area and inhibited vascular NADPH oxidase activity and
oxidative stress in ApoE/ mice fed a high fat diet.20
Epidemiological data suggest that higher vegetable nitrate intake
is associated with a lower CIMT and a lower risk of ischaemic
cerebrovascular disease events and atherosclerotic vascular disease
mortality in 1226 older women,21,22 and of new cases of cardiovascu-
lar disease-related complications over 15-years of follow-up in 5324
middle-aged women.23
However, direct evidence in humans is scarce, with no
randomized-controlled trial data reported to date on whether chronic
supplementation with dietary nitrate affects carotid structure and
stiffness. To our knowledge, there is only 1 study testing the effects
of organic nitrates on CIMT: Sekiya et al.,24 studied 42 patients with
ischaemic heart disease randomly allocated to receive 3 months'
nicorandil (15 mg daily) or isosorbide dinitrate (ISDN; 40 mg daily).
However, they found that ISDN increased/worsened CIMT, whilst
nicorandil had no effect.24 In contrast to inorganic nitrate/nitrite,
organic nitrates are associated with impairment of endothelial
function and tolerance/loss of effect. Indeed, in that study, ISDN was
found to worsen brachial artery flow mediated dilatation.
This contrasts with antihypertensives, some of which have been
extensively studied for their effects on CIMT. Mineralocorticoid
receptor antagonists such as spironolactone have been shown to
reduce the progression of CIMT over 2 years in nondiabetic patients
on haemodialysis treated vs. placebo.25 In an uncontrolled study,
eplerenone was found to improve CIMT in patients with primary aldo-
steronism over 6 and 12 months, though this was also associated with
decreased blood pressure (BP).26 Over a prolonged period of 6 years,
treatment of patients with primary aldosteronism with spironolactone
had a similar significant effect on regression of CIMT as surgical treat-
ment in patients with unilateral forms of primary aldosteronism, with
no significant difference in BP between treatments.27 However,
whether spironolactone confers specific effects on CIMT vs. other
antihypertensives/independently of BP has not been tested.
Thus, in a subgroup of participants who took part in our VaSera
trial, we performed serial carotid ultrasound scans to a priori evaluate
the effect of dietary nitrate on carotid structure and function. We
have already reported on the primary outcome of the main study,
which was to assess whether 6 months' intervention with dietary
nitrate (vs. placebo), spironolactone (vs. doxazosin) or both (in a
factorial design) could reduce arterial stiffness independently of
BP,28,29 and the echocardiography subgroup findings.30
2 | METHODS
2.1 | Study design and interventions
Among the patients with or at risk of T2DM who took part in the
double-blind, randomized-controlled, factorial VaSera trial, a sub-
population had carotid ultrasound performed at baseline and
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throughout the study as part of the cardiovascular measurements.
Recruitment occurred between 2013 and 2015 at Guy's and
St. Thomas' Hospitals, London, UK and surrounding areas. Inclusion
criteria were age between 18 and 80 years; clinical diagnosis or at risk
of T2DM (i.e. body mass index ≥27 kg/m2, positive family history or
glucose intolerance after 75 g challenge); capability of understanding
and following the protocol. Exclusion criteria included interfering
chronic illness, allergy/intolerance to either drug and/or beetroot,
eGFR <45 mL/min, HbA1c > 11% (97 mmol/mol), pregnancy, breast
feeding or atrial fibrillation. The study protocol was approved by
South London Research Ethics Committee. After being consented at
visit 1 (V1), participants were randomized at visit 2 (V2) to spi-
ronolactone (12.5 mg titrated to 25 mg, twice daily) or doxazosin (4 to
8 mg, twice daily) and dietary nitrate as Beet It beetroot juice
(HeartBeet Ltd., Suffolk, UK, 4.5 mmol nitrate increased to 11.2 mmol
once daily) or nitrate-free Beet It juice, a specific placebo,
recommended to be taken daily with their existing treatment. Cardio-
vascular measures were performed at baseline (V2) and repeated at
3 months (visit 5, V5) and 6 months (visit 6, V6). The results for
primary outcome, aortic arterial stiffness (measured using aortic pulse
wave velocity [PWV]), central systolic pressure and augmentation are
published elsewhere.28 Peripheral BP was measured according to
guidelines,31 using a validated BP monitor (Intellisense 705IT, Omron,
UK). Carotid ultrasound was performed by 2 expert operators, using a
GE Vivid 7 Ultrasound System, and all images analysed by a single
operator blinded to the intervention. Acquisitions respected the
current recommendations for ultrasound evaluation of carotid arteries
and common CIMT measurement32,33 Carotid ultrasound image
sequences were analysed using a highly automated method (Carotid
Analyzer, Medical Imaging Application, LLC) for detection of near and
far wall border, detection of near and far intima border, vessel diame-
ter measurement, and CIMT measurement. Additional carotid parame-
ters were calculated as follows: diameter distension (ΔD, mm), the
difference between systolic and diastolic diameter; diameter distensi-
bility (%), the diameter distension with respect to the diastolic
diameter; area distension (mm2), the difference between systolic and
diastolic carotid lumen area; diameter compliance (mm/mmHg), the
diameter distension with respect to pulse pressure (which is the
difference between central systolic [SBP] and diastolic [DBP] BP);
cross sectional distensibility (CSD, %), the area distension with respect
to the diastolic area; cross sectional compliance (mm2/mmHg), the
area distension with respect to the pulse pressure; CSD coefficient
(kPa1  103), cross sectional compliance with respect to the pulse
pressure; carotid stiffness, (CS, m/s), CSD coefficient corrected by
blood density according to the Moens–Korteweg Equation.34 A visual
summary of the timing of interventions and measurements is shown
in Figure 1.
2.2 | Statistical analysis
This was a prespecified/prospectively conducted, exploratory mecha-
nistic part of the main VaSera trial, performed in a subgroup who had
carotid imaging as part of their baseline and follow-up visits. The main
trial was powered to detect a 20% (SD 8%) reduction in the primary
outcome of PWVart with spironolactone, with minimum 80% power,
at P < .05, requiring a sample size of 24 participants each arm, aiming
for 30 to allow a 20% drop-out.35 The sample size was achieved in
F IGURE 1 Study flow diagram. At Visit 2, participants were randomised to 1 of the 4 intervention arms and underwent baseline carotid
ultrasound. Three months after (Visit 5), participants had follow-up imaging and doubled their dosage regimen as planned. A further 3 months
after (Visit 6), participants had their last follow-up imaging
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the main trial, with 126 patients randomised, and 110 and
106 patients completing mid-point and end of trial, respectively. An
effect on CIMT was a tertiary outcome. Our independent biostatisti-
cian conducted a modified intention-to-treat analyses using SAS
(Version 9.3) and included in the analysis all randomised participants
with at least 1 outcome data at any follow-up visit but planned to
exclude any randomised patient who failed to received study medica-
tion or provided no follow-up for the primary outcome variable. The
effect of the interventions was estimated using mixed-effects models,
adjusted for sex, age, ethnicity (European, African-Caribbean, West
African and others) and diagnosis of T2DM baseline value of the out-
come as covariates. As per the statistical analysis plan, the models
included an interaction term for drug  nitrate juice, which allowed us
to test for nonadditive effects. If no statistical interactions are
detected between the juice and drug arms, the data are presented
separately. The models also included baseline covariates and the base-
line value of the covariate being analysed. Our data are exploratory
and hypothesis-generating, rather than confirmatory and hypothesis-
testing, thus, results are presented as least-square mean changes from
baseline and difference between drugs and juices, averaged over both
follow up visits for each outcome, with 95% CIs; in accordance with
the recent editorial, Statistical reporting of clinical pharmacology
research.36 P-values are included when useful to demonstrate a
statistically significant difference between interventions.
3 | RESULTS
Of the study participants, 93 had a baseline carotid ultrasound
(V2) and 81 (86%) had follow-up imaging at V5 and V6 (Figure 2). No
statistical interactions were detected between active beetroot or
placebo juice arms and the spironolactone or doxazosin arms for any
of the haemodynamic or carotid outcomes, so data are presented
separately. Baseline characteristics of the study population are listed
in Table 1. Haemodynamic and carotid parameters compared to
baseline are summarised in Table 2.
SBP and DBP did not differ between nitrate-containing and
nitrate-depleted juice or between spironolactone and doxazosin
(Table 2).
Data confirming adherence to the beetroot juice arm in the main
study are published by Mills et al.28 Baseline CIMT was similar across
each intervention group, e.g. 0.72 mm in the placebo and 0.75 mm in
the active juice group (Table 1). Compared to placebo juice, active
nitrate-containing beetroot juice lowered CIMT (0.06 mm [95%
confidence interval 0.12, 0.01], P = .034; Table 2, Figure 3); thus,
representing a difference of 8% relative to baseline. Compared to
baseline, CIMT increased with the nitrate-depleted (0.05 mm [0.02,
0.09], P = .005; Table 2, Figure 3A).
Compared to placebo juice, active nitrate-containing beetroot
juice resulted in no differences in maximum or minimum carotid
diameter (CD; Table 2; Figure 4), or the difference between systolic
and diastolic carotid diameter ΔD, diameter compliance, distensibility,
cross-sectional compliance or CSD, or CS (Table 2; Figure 5).
Compared to doxazosin, spironolactone had no effect on CIMT,
CD or CS. CS was reduced from baseline with doxazosin (0.34 mm
[0.62, 0.06], P = .018), but not with spironolactone (0.15 mm
[0.46, 0.16]; Table 2).
4 | DISCUSSION
Our study shows that 6 months' dietary nitrate as beetroot juice
reduces CIMT, a marker of subclinical atherosclerosis, compared to
nitrate-depleted placebo juice. This effect was independent of BP,
F IGURE 2 Consolidated standards of
reporting trials (CONSORT) flow diagram for the
VaSera trial, and subsample of participants who
had carotid imaging at baseline and follow-up
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which did not differ between nitrate-rich and placebo juice, in line
with the results from the overall study.28,30 The absence of changes in
other morphological measures, such as carotid diameters in systole
and diastole, supports a mechanism whereby nitrate has chronic,
sustained actions predominantly on the most internal layer, the intima,
rather than transient, reversible effects on smooth muscle of the
media. No other comparative differences were found with either
nitrate vs. placebo juice or spironolactone vs. doxazosin: notably, in
contrast to nitrate, spironolactone was without effect on CIMT com-
pared to doxazosin.
The effects of dietary nitrate on BP are well-described,37–39 and
there is growing interest around its role for the reduction of cardio-
vascular risk.40 Our findings highlight the potential of dietary nitrate
to decelerate the atherosclerotic process in a population at increased
risk, and this is the first randomized, placebo-controlled clinical trial
demonstrating such an effect in humans. As we described in the Intro-
duction, thickening of the carotid intima-media on ultrasound is an
early marker of atherosclerosis, and the early involvement of the
intima in the atherogenic process is well-established.7–9 Also, dimin-
ished production and availability of NO are important factors in the
earliest phases of atherogenesis.10 Thus, dietary nitrate might be use-
ful to supply the endothelium with NO and prevent oxidative stress,
alongside other measures to control risk factors for atherosclero-
sis.11,12,15 Indeed, as we described above, evidence of beneficial
effects of long-term dietary nitrate on atherosclerosis has been previ-
ously reported from some, but not all studies performed in rats and
Apo E/ mice,18–20 and an association has been observed in epidemi-
ological studies.21,22 The cohort study by Bondonno et al.21 which
included older Australian women aged 70–85 years, and without
prevalent atherosclerotic vascular disease and/or diabetes, evaluated
the nitrate intake from vegetables. Higher vegetable nitrate intake
was associated with lower CIMT: for each 1 standard deviation or
29 mg/d (i.e. 0.5 mmol/d) increase in nitrate intake, CIMT was
decreased (0.012 mm, P = .006); this was associated with a 17%
lower risk of 14.5-year ischaemic cerebrovascular events,21 and
diminished atherosclerosis related mortality.41 In our study, the nitrate
intake was 7.5 mmol/d for 3 months, which was increased to
11.2 mmol/d from 3–6 months and resulted in a decrease in CIMT
of 0.06 mm (vs. nitrate-free Beet It juice) over 6 months. To our
knowledge, our study provides the first randomized, placebo-
controlled trial evidence for the potential favourable direct effect of
dietary nitrate on CIMT, and in a population comprising high risk
males as well as females. Very recently, a single-arm, open-label phase
2 proof of concept study by Hughan et al., showed that 12 weeks' of
TABLE 1 Baseline characteristics of the study population.
Doxazosin Spironolactone
Placebo juice Active juice Placebo juice Active juice
Patients n 22 17 21 21
Sex, female n (%) 7 (32) 5 (29) 8 (38) 8 (38)
Type 2 diabetes n (%) 16 (73) 11 (65) 15 (71) 11 (52)
Cardiovascular events n (%) 1 (5) 2 (12) 2 (10) 2 (10)
Smoker n (%) 2 (9) 2 (12) 2 (12) 1 (5)
Age (y) Mean (SD) 59.1 (11.3) 57.8 (14.6) 57.4 (12.1) 56.6 (15)
BMI (kg/m2) Mean (SD) 32.3 (5.8) 32.6 (7.8) 33.2 (5.7) 31.6 (4.3)
SBP (mmHg) Mean (SD) 142.2 (20.74) 130.6 (19.05) 131.6 (14.08) 141 (25.98)
DBP (mmHg) Mean (SD) 81.7 (13.3) 75.4 (12.2) 80.1 (11.2) 83.1 (13.5)
CIMT (mm) Mean (SD) 0.72 (0.16) 0.75 (0.18) 0.71 (0.23) 0.75 (0.14)
Max CD (mm) Mean (SD) 7.99 (1.07) 7.99 (0.85) 7.84 (1.22) 8.11 (0.84)
Min CD (mm) Mean (SD) 7.43 (1.02) 7.53 (0.80) 7.31 (1.13) 7.51 (0.84)
ΔD (mm) Mean (SD) 0.28 (0.16) 0.36 (0.13) 0.31 (0.19) 0.24 (0.09)
DD (%) Mean (SD) 0.85 (0.16) 0.77 (0.09) 0.83 (0.14) 0.89 (0.14)
ΔA (mm2) Mean (SD) 0.8 (0.16) 0.73 (0.13) 0.76 (0.19) 0.85 (0.14)
DC (mm/mmHg) Mean (SD) 1.95 (0.20) 1.99 (0.16) 2.01 (0.22) 1.97 (0.13)
CSD (%) Mean (SD) 1.17 (0.16) 1.08 (0.09) 1.15 (0.19) 1.21 (0.14)
CSC1 (mm2/mmHg) Mean (SD) 0.88 (0.20) 0.91 (0.16) 0.94 (0.22) 0.89 (0.13)
CSDc (kPa1 x 103) Mean (SD) 2.49 (0.20) 2.55 (0.16) 2.56 (0.22) 2.52 (0.18)
CS (m/s) Mean (SD) 5.53 (1.35) 5.91 (1.20) 6.02 (1.43) 5.74 (1.21)
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CIMT, carotid intima-media thickness; Max CD, maximum (systolic)
carotid diameter; min CD, minimum (diastolic) carotid diameter; ΔD, difference between systolic and diastolic carotid diameter; DD, diameter distensibility;
ΔA, difference between systolic and diastolic carotid lumen; DC, diameter compliance; CSD, cross sectional distensibility; CSC1, cross sectional
compliance; CSDc, cross sectional distensibility coefficient; CS, carotid stiffness. SD, standard deviation
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 MORSELLI ET AL.
oral sodium nitrite (40 mg 3 times a day) reduced CIMT by 0.04 mm
from 0.773 ± 0.02 mm at baseline to 0.730 ± 0.02 at 12 weeks
(P = .0054) in 20 patients with hypertension and metabolic syn-
drome.42 This study provides valuable mechanistic support for an
effect of nitrite on CIMT, albeit accompanied by a significant decrease
in semi-recumbent SBP and DBP and a significant 11% increase in
resting conduit artery diameter (brachial) from 0.36 ± 0.02 mm to
0.40 ± 0.02 mm after 12 weeks of nitrite therapy (P = .0009); this is
similar to the acute vasodilatory effect of systemically-infused nitrite
we had previously observed.43 As commented above, our observed
effect of dietary nitrate on CIMT was in the absence of changes in BP
or carotid diameter.
Whilst not part of the main comparative analysis, inspection of
the remaining data reveals that there was evidence of a decrease in
CS from baseline with placebo juice and with doxazosin, (also, similar
nonsignificant trends for nitrate-rich juice and for spironolactone).
However, no difference was found between the juices, or the
between drugs, for CS reduction. We recently reported, as part of
the main findings of this VaSera study, that doxazosin decreased arte-
rial stiffness as aortic PWV.28 Similar to its effect on muscular arteries,
doxazosin is likely to reduce vascular tone and arterial stiffness in
larger elastic arteries, such as the aorta and its branches. Differences
in measurement techniques between aortic stiffness (measured using
PWV) and carotid stiffness (measured using echo-tracking) and sample
size may account, at least in part, for the lack of a significant effect of
doxazosin (vs. spironolactone) on CS. In addition, previous studies
have shown that risk factors such as high BP and type 2 diabetes
stiffen the aorta more than the carotid.44 Thus, the aortic response to
doxazosin (PWV) might have been more evident than the carotid
response (CS), in a population such as ours with these risk factors.
Also, we have recently found that the relationship between circulating
plasma nitrite concentration and pulse pressure, which is related to
large artery stiffness, is more complex than we anticipated, albeit in
an acute crossover study. Whilst active beetroot juice significantly
decreased pulse pressure vs. placebo juice, addition of grapefruit juice,
further decreased pulse pressure despite decreasing plasma nitrite
concentration.45
Overall, our results show that dietary nitrate influences vascular
remodelling, probably acting on those layers of the vascular wall that
are mainly involved in the atherogenic process. This might be due to
the provision of an alternative source of NO, in the face of diminished
NO production seen in the early stages of atheroma formation.
We acknowledge that current guidelines in Europe46 and the
USA47 do not recommend routine CIMT evaluation as part of the car-
diovascular risk assessment, and this is mainly due to conflicting
results and lack of standardisation of measurements methods. CIMT
remains an established marker of subclinical atherosclerosis, and fur-
ther research is needed to clarify its role in the cardiovascular risk
evaluation of asymptomatic individuals.9,48
Whilst this was a well-controlled study (double blind placebo for
nitrate) and the first trial of its kind for dietary nitrate—with 6 months'
intervention, there were several limitations. For example, CIMT,
together with other carotid vascular parameters, were not the primary
outcome of the VaSera trial. Also, a relatively small subsample of
81 patients had follow-up data. Thus, our analysis is exploratory, and
our results require further confirmation from larger studies. We did
not assess physical activity and we had decided in the original design
of the study, that habitual diet, including dietary nitrate intake, would
not be controlled for, as we wished to reflect a real-world situation,
and thus this could also be viewed as a strength; this was intentionally
a pragmatic trial. Instead, we measured plasma nitrate and nitrite con-
centrations in the main study and found that they were elevated in
patients on active (nitrate-containing) vs. placebo (nitrate-depleted)
beetroot juice,28 providing evidence of reasonable adherence and
with an elevation above a variable background nitrate intake. Whilst
food frequency questionnaires have some limitations, the develop-
ment of a reference database for assessing dietary nitrate in
vegetables,49 which can be used in conjunction with a food frequency
questionnaire, provides a useful tool for future interventional studies,
F IGURE 3 Effect of dietary nitrate as beetroot juice on carotid
intima-media thickness (CIMT) measured by B-mode ultrasound.
(A) Change from baseline in CIMT for active nitrate-rich juice and
placebo nitrate-depleted juice. (B) Overall effect of active juice vs.
placebo juice on CIMT. Data shown as least-square means with 95%
s. *P < .05
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F IGURE 4 Effect of dietary nitrate as beetroot juice on carotid diameter (CD) measured by B-mode ultrasound. Change from baseline in
maximum (A) and minimum (C) CD for active nitrate-rich juice and placebo nitrate-depleted juice. Overall effect of active juice vs. placebo juice on
maximum (B) and minimum (D) CD. Data shown as least-square means with 95% confidence intervals
F IGURE 5 Effect of dietary nitrate as beetroot juice on carotid stiffness (CS) measured by B-mode ultrasound. (A) Change from baseline in CS
for active nitrate-rich juice and placebo nitrate-depleted juice. (B) Overall effect of active juice vs. placebo juice on CS. Data shown as least-
square means with 95% confidence intervals
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besides the observational/epidemiological studies. Also, we have
recently found that environmental nitrogen dioxide, including from
gas appliances such as gas cookers, increases plasma nitrite
concentration and lowers SBP and DBP.50 Thus there is potential for
confounding of the effect of dietary nitrate-derived circulating nitrite
by nitrogen dioxide-derived circulating nitrite from atmospheric
pollution and domestic gas appliances.
5 | CONCLUSION
CIMT was lower after 6 months of active beetroot juice intake com-
pared to placebo juice. Other vascular parameters, such as carotid
diameter and stiffness, did not differ between interventions. Thus, our
results suggest that dietary nitrate might have a beneficial effect on
intima-media remodelling, which is involved in atherogenesis, and thus
represent a potential intervention to prevent or treat atherosclerosis.
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